Fibralign Corporation
Sunnyvale · Founded 2007
About Fibralign Corporation
Fibralign Corporation utilizes Nanoweave® a proprietary scaffolding technology to develop advanced biomedical devices. Fibralign has launched its first product, the BioBridge® Collagen Matrix, and is now engaging in clinical studies to evaluate its use for treating and preventing secondary lymphedema, as well as advancing R&D development for new applications for treating ischemia and novel delivery devices for use with stem cells and gene therapy.
Company Facts
- Founded: 2007
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $180.0K
- Last round: Series Unknown (Nov 2017)
- Website: fibralignbio.com
- Phone: 8313358348
Social Profiles
Canonical: https://fsome.com/organization/fibralign-corporation-8355952 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.